Oncology & Cancer

Patient preferences explored in multiple myeloma treatment

(HealthDay)—An Eastern Cooperative Oncology Group (ECOG) performance status of ≥2 is linked to lower treatment satisfaction in patients with relapsed or refractory multiple myeloma (RRMM), but receiving medication orally ...

Oncology & Cancer

MGUS can progress to multiple myeloma within five years

(HealthDay)—Individuals with low- or intermediate-risk monoclonal gammopathy of undetermined significance (MGUS) can experience progression to multiple myeloma within five years, according to a study published online July ...

Medical research

Target found to arrest cancer growth

Adelaide researchers are homing in on a new treatment target for the aggressive blood cancer multiple myeloma.

Medications

Daratumumab cuts risk for progression in multiple myeloma

(HealthDay)—For patients with newly diagnosed multiple myeloma, the addition of daratumumab to lenalidomide and dexamethasone is associated with a reduced risk for disease progression or death, according to a study published ...

page 13 from 36